Castro, T B M <br/><br/>
Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide.  [electronic resource] 

 -  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas  2016 
 - e5128 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Observational Study 
<br/><br/><label>ISSN: </label>1414-431X 
<br/><br/><label>Standard No.: </label>10.1590/1414-431X20165128  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bortezomib--adverse effects<br/>Diarrhea--chemically induced<br/>Female<br/>Humans<br/>Immunosuppressive Agents--adverse effects<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Neutropenia--chemically induced<br/>Peripheral Nervous System Diseases--chemically induced<br/>Pharmacovigilance<br/>Prospective Studies<br/>Risk Factors<br/>Thalidomide--adverse effects<br/>Treatment Outcome